Tunable, proteolytic dosage control of CRISPR-Cas systems enables precise gene therapy for dosage sensitive disorders
- DOI
- 10.1101/2024.10.09.617463
- Published
- 2024-10-09
- Container
- Not recorded
- Publisher
- Not recorded
- Open access
- no
Credibility signals
limited evidence Score 39/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- cautionPublication version: Identified as a preprint; peer review and later versions may change the record.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1101/2024.10.09.617463,
title = {Tunable, proteolytic dosage control of CRISPR-Cas systems enables precise gene therapy for dosage sensitive disorders},
author = {Katz N and An C and Lee Y and Tycko J and Zhang M and Kang J and Bintu L and Bassik MC and Huang W and Gao XJ.},
year = {2024},
doi = {10.1101/2024.10.09.617463},
url = {https://doi.org/10.1101/2024.10.09.617463}
}RIS
TY - JOUR TI - Tunable, proteolytic dosage control of CRISPR-Cas systems enables precise gene therapy for dosage sensitive disorders AU - Katz N AU - An C AU - Lee Y AU - Tycko J AU - Zhang M AU - Kang J AU - Bintu L AU - Bassik MC AU - Huang W AU - Gao XJ. PY - 2024 DO - 10.1101/2024.10.09.617463 UR - https://doi.org/10.1101/2024.10.09.617463 ER -
APA
N, K., C, A., Y, L., J, T., M, Z., J, K., L, B., MC, B., W, H., & XJ., G. (2024). Tunable, proteolytic dosage control of CRISPR-Cas systems enables precise gene therapy for dosage sensitive disorders. https://doi.org/10.1101/2024.10.09.617463
Source records
- europe-pmc · retrieved 2026-09-27T04:43:38.820Z